Micaela G.

Professor in medical education at IUCS. Fundación H.A Barcelo
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Buenos Aires, Buenos Aires Province, Argentina, AR
Languages
  • Inglés Native or bilingual proficiency

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
Join now
You need to have a working account to view this content.
Join now

Credentials

  • Curso de Monitoreo de estudios clínicos
    FEFyM
    Mar, 2022
    - Oct, 2024
  • Minimum Criteria for ICH E6 (R2) GCP Investigator Site Personnel Training
    TransCelerate BioPharma Inc.
    Oct, 2021
    - Oct, 2024
  • Curso de Data Analytics
    Ministerio de Trabajo, Empleo y Seguridad Social
    Jun, 2021
    - Oct, 2024
  • Normas de Buena Prácticas Clínicas ICH E6 (R2)
    The Global Health Network
    Jun, 2021
    - Oct, 2024
  • Curso Intensivo de Inmunizaciones
    Fundacion Vacunar
    May, 2020
    - Oct, 2024

Experience

  • Fundación Barceló
    • Argentina
    • Higher Education
    • 200 - 300 Employee
    • Professor in medical education
      • Aug 2022 - Present

      JEFA DE TRABAJOS PRACTICOS de la catedra BASES BIOLOGICAS Y ANTROPOLOGICAS DE LA VIDA de la carrera de MEDICINA. JEFA DE TRABAJOS PRACTICOS de la catedra BASES BIOLOGICAS Y ANTROPOLOGICAS DE LA VIDA de la carrera de MEDICINA.

  • Mepryl- Medicina preventica
    • Provincia de Buenos Aires, Argentina
    • Medical Doctor
      • Jan 2023 - May 2023

  • Pfizer
    • United States
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Sub-investigator in Clinical Trial of PreF Subunit Vaccine against RSV.
      • Nov 2021 - May 2022

      Phase 3 study to evaluate the efficacy, immunogenicity and safety of the respiratory syncytial virus (RSV) F-sub unit infusion vaccine in adults.

    • Sub-investigator in Clinical Trial of Vaccine against COVID-19
      • Oct 2021 - May 2022

      C4591001, Phase1/2/3, Randomized, Observer-Blinded, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of Potential SARS-COV-2 RNA Vaccines Against COVID-19 in healthy adults.

  • Medicago
    • Canada
    • Biotechnology Research
    • 200 - 300 Employee
    • Sub-investigator in Clinical Trial of Vaccine against COVID-19
      • Jun 2021 - May 2022

      CP-PRO-CoVLP-021, Phase 2/3, Randomized, Observer Blinded, Placebo-Controlled Study to Evaluatethe Safety, Efficacy, and Immunogenicity of a Recombinant Particulate Vaccine similar to coronavirus against COVID-19 in adults 18 years and older. CP-PRO-CoVLP-021, Phase 2/3, Randomized, Observer Blinded, Placebo-Controlled Study to Evaluatethe Safety, Efficacy, and Immunogenicity of a Recombinant Particulate Vaccine similar to coronavirus against COVID-19 in adults 18 years and older.

  • I- TRIALS
    • Buenos Aires, Argentina
    • Clinical Trial Sub Investigator
      • Jun 2021 - May 2022

      I developed my activities as a Sub Investigator at the Central Military Hospital of Buenos Aires, Argentina. There I worked for several protocols, which were: - CP- PRO- CoVLP 021. MEDICAGO - C4591001. PFIZER. - C3671013. PFIZER. I developed my activities as a Sub Investigator at the Central Military Hospital of Buenos Aires, Argentina. There I worked for several protocols, which were: - CP- PRO- CoVLP 021. MEDICAGO - C4591001. PFIZER. - C3671013. PFIZER.

  • HOSPITAL NAVAL
    • Argentina
    • Hospitals and Health Care
    • 100 - 200 Employee
    • Medica de Guardia
      • May 2021 - May 2022

Education

  • Galway cultural institute
    Lengua y literatura inglesa
    2022 - 2023
  • Instituto Universitario de Ciencias de la Salud - Fundación Héctor A. Barceló.
    Médica, Medicina
    2015 - 2021

Community

You need to have a working account to view this content. Click here to join now